Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women

Abstract

The LRP5 c.266A > G and c.3893C > T polymorphisms may be associated with risk of nonresponse to HT in postmenopausal Korean women.

Pharmacogenetics of Metabolic Bone Diseases

“…Both the studies evidenced that, despite the presence of LRP5 mutation, the administration of bisphosphonates resulted in an improving of lumbar spine BMD Z-score and a decreasing of bone pain [17] and in an increased BMD value and a decreased fracture rate [18]. Conversely, Kim et al [8] demonstrated that the T allele of LRP5 C3893T and the G allele of LRP5 A266G polymorphisms were associated with a higher risk of non response, respectively in terms of lumbar spine and femoral neck BMD gain and only of lumbar spine BMD gain, in postmenopausal Korean women treated with HRT.…”

“…The great majority of studies on pharmacogenetics of osteoporosis have analyzed the role of genetic variants of previously known osteoporosis candidate genes [i.e estrogen receptors alpha (ERα) and beta (ERβ), vitamin D receptor (VDR), collagen I alpha 1 (COL1A1), lipoprotein receptor-related protein 5 (LRP5)] in the modulation of response to commonly used anti-osteoporotic drugs, such as hormone replacement therapy (HRT) [1][2][3][4][5][6][7][8], raloxifene [9,10] and bisphosphonates (BPs) [11][12][13][14][15][16].…”

“…Many of published osteoporosis pharmacogenetics studies [1][2][3][4][5][6][7][8][9][10][11][12][13]16] showed positive statistical associations between common polymorphisms of osteoporosis major candidate genes and the response to anti-resorptive drugs in treated patients, valuated in terms of bone mineral density (BMD) changes and variations of serum and/ or urinary bone turn-over markers (Table 1).…”